Please wait while the formulary information is being retrieved.
CYFENDUS (NATIONAL STOCKPILE) (anthrax vaccine adsorbed, adjuvanted)
- treatment to prevent anthrax after exposure to disease
0.5 mL/dose intramuscular suspension
- Dosage information is not available
- None
Contraindicated
- fingolimod
- Gilenya
Severe
Moderate
- None
- None
Contraindicated
- Pregnancy
Severe
Moderate
- None
CYFENDUS (NATIONAL STOCKPILE) (anthrax vaccine adsorbed, adjuvanted)
- treatment to prevent anthrax after exposure to disease
- None
- Fatigue
- Injection site erythema
- Injection site inflammation
- Injection site pain
- Injection site sequelae
- Myalgia
- Pharyngitis
More Frequent
Severe
Less Severe
- Hypersensitivity drug reaction
- Back pain
- Diarrhea
- Headache disorder
- Lymphadenopathy
- Skin rash
- Upper respiratory infection
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Anaphylaxis
- Pruritus of skin
- Rhabdomyolysis
- Urticaria
Less Severe
- Arthralgia
- Chills
- Fever
- Flushing
- Insomnia
- Nausea
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Anthrax Vaccine
Safety and efficacy not established.
- 1 Day – 18 Years
- Safety and efficacy not established.
Anthrax Vaccine
- Severity Level:
D
- Additional Notes: Observational study data show potential risk for birth defects
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Anthrax Vaccine
Insufficient human data available
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient human data available |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Post-exposure anthrax prevention | |
| Z20.810 | Contact with and (suspected) exposure to anthrax |
| 0-9 | A-Z |
|---|---|
| Z20.810 | Contact with and (suspected) exposure to anthrax |
Formulary Reference Tool